Leading the charge

Led by a mission-driven team, Innoviva Specialty Therapeutics blends rigorous medical science with proven industry experience

Executive Team

Matt Ronsheim, President

Matt Ronsheim, PhD


Dr. Matt Ronsheim is an accomplished leader with over two decades of pharmaceutical development and commercialization experience. He has built and led teams throughout his career that have delivered groundbreaking therapies from preclinical, through all stages of clinical development, global regulatory approvals, and ultimately commercial launch and supply. Dr. Ronsheim has held influential leadership roles at Enanta Pharmaceuticals, Merck/Cubist, and Forest Laboratories and delivered pioneering therapies across diverse disease areas including anti-infectives, central nervous system disorders, and gastrointestinal conditions. He holds a BS in Chemistry from Southern Connecticut State University and a PhD in Synthetic Organic Chemistry from the University of New Hampshire.

David Altarac, M.D.

David Altarac, M.D.

Chief Medical Officer

Dr. Altarac is an infectious diseases physician and pharmaceutical executive with more than 20-years’ experience leading clinical and regulatory functions. He previously served as the Chief Medical Officer of Entasis Therapeutics and held leadership positions at Shire Pharmaceuticals, NeoStem, Inc., and Merck & Co. in therapeutic areas including infectious diseases, oncology, ophthalmology, inflammation, and rare diseases. Dr. Altarac holds an M.D. degree from New York Medical College, a Master of Public Administration (M.P.A.) degree from New York University, and a B.A. in Chemistry from the State University of New York at Binghamton, NY.

Pavel Raifeld, CFA

Chief Executive Officer, Innoviva

Pavel brings deep financial and strategic expertise from experiences at Sarissa Capital Management, Credit Suisse’s healthcare investment banking, and biopharmaceutical consulting at McKinsey & Company and BCG. He holds a BA from Harvard and an MBA from Columbia University.

Steve Basso

Chief Financial Officer, Innoviva

Mr. Basso brings more than 30 years of experience of financial leadership, primarily in the pharmaceutical industry. Prior to joining Innoviva, Mr. Basso served as the Chief Financial Officer and Chief Operating Officer at Cybrexa Therapeutics and has held a variety of financial leadership positions at Inozyme Pharma, Alexion Pharmaceuticals and Pfizer. He received a BS in business from Providence College and an MBA from Boston College.

Marianne Zhen

Chief Accounting Officer, Innoviva

Joining Innoviva in 2014, Marianne previously served as Corporate Controller for three tech companies. A member of the AICPA and the CalCPA, she also served on the CalCPA Peninsula Silicon Valley Chapter board. Marianne holds a BS in Business Administration from San Francisco State University.


Join a team where all colleagues can do their best work while making a lasting impact.

Learn More